Clinical Research Directory

Inclusion Criteria: * 1.Provide written informed consent before any study procedures. 2.Be 18 years of age or older; male or female. 3.Weigh at least 50 kg if male or 45 kg if female, with a body mass index (BMI) of 19.0 to 26.0 kg/m², inclusive. 4.Have vital signs, physical examination, 12-lead ECG, and clinical laboratory test results (including hematology, urinalysis, blood chemistry, coagulation, infectious disease screening, and pregnancy testing for females) that are normal or considered not clinically significant by the investigator. 5.Have no plans to become pregnant, father a child, or donate sperm or eggs through 90 days after the last dose, and agree to use non-drug contraception during the study. Exclusion Criteria: * 1.History of allergy to two or more drugs, foods, or environmental substances; allergy to azilsartan medoxomil potassium, similar drugs, or any tablet excipient. 2.Current or previous severe or chronic disease considered clinically significant by the investigator, including musculoskeletal, gastrointestinal, endocrine, respiratory, urinary, reproductive, cardiovascular, or neurological disease. 3.Previous surgery considered likely to affect drug absorption, distribution, metabolism, or excretion, including liver, kidney, or gastrointestinal resection, or planned surgery during the study. 4.Vaccination within 4 weeks before the first dose, or planned vaccination during the study. 5.Use of any prescription or nonprescription medication, traditional Chinese medicine, or health supplement within 14 days before the first dose. 6.Participation in another clinical trial involving a drug, vaccine, or medical device within 3 months before the first dose. 7.Blood donation or substantial blood loss (≥400 mL) within 3 months before the first dose, or planned blood donation through 1 month after the last dose. 8.Regular alcohol consumption exceeding 14 units per week during the 6 months before the study; unwillingness to abstain from alcohol during the study; or a positive alcohol test. 9.Average smoking of ≥5 cigarettes per day during the 3 months before screening, or inability to abstain from nicotine-containing products during the study. 10.Drug abuse within 12 months before the first dose, or a positive urine drug screen. 11.Inability to tolerate venipuncture or a history of fainting related to needles or blood. 12.Lactose intolerance. 13.Special dietary requirements that prevent compliance with the study diet. 14.Consumption of foods such as grapefruit, strenuous exercise, or other factors that may affect drug absorption, distribution, metabolism, or excretion within 7 days before the first dose. 15.Consumption of more than 8 cups of tea, coffee, or other caffeinated beverages per day during the 3 months before screening, or consumption of caffeine-containing or xanthine-rich foods or drinks within 48 hours before the first dose. 16.Use of oral contraceptives within 30 days before the first dose, or use of long-acting estrogen or progesterone injections or implants within 6 months before the first dose (females). 17.Pregnancy or breastfeeding, or unprotected sexual intercourse within 14 days before screening (females). 18.Inability to participate for personal reasons. 19.Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.